Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares US Aerospace & Defense ETF (ITA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares US Aerospace & Defense ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.04 (market cap $2.81B), while iShares US Aerospace & Defense ETF trades at $204.71 (market cap $11.78B). The key difference: iShares US Aerospace & Defense ETF is far larger — about 4.2× Dyne Therapeutics Inc. Common Stock's market cap, and iShares US Aerospace & Defense ETF is more actively traded (683,952 versus 2,195,902). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares US Aerospace & Defense ETF for 24 Days on average.
| DYN | ITA | |
|---|---|---|
Market Cap | $2.81B | $11.78B |
Volume | 2,195,902 | 683,952 |
Sector | Health | Sector/Thematic |
52-Week High | $26.78 | $253.22 |
52-Week Low | $14.60 | $198.23 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $2.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
ITA trades at $204.00, down 0.99% with bearish technical signals from moving averages. The ETF shows neutral oscillators but faces selling pressure with RSI at oversold levels. Recent corporate actions include a 1:3 stock split scheduled for November 2026 and a $0.25 dividend payment in September 2026. Defense sector momentum remains strong with multiple contract wins and geopolitical tensions driving demand.
The defense sector outlook appears favorable with increased government spending and geopolitical tensions, though ITA faces technical headwinds. Key risks include defense budget volatility and geopolitical resolution. Analyst sentiment remains mixed with the ETF positioned to benefit from ongoing military modernization programs and replenishment of defense inventories.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares US Aerospace & Defense ETF
iShares U.S. Aerospace & Defense ETF seeks to track U.S. companies in the aerospace and defense sector. Its holdings include manufacturers of commercial and military aircraft, defense systems, and related equipment.
Read more on ITA →
